Thus, experts commonly define three different BC subtypes: luminal-like (ER-positive and/or PgR-positive and HER2-negative), HER2-positive (HER2 overexpression/amplification, with any ER and PgR expression), and triple negative (ER-negative, PgR-negative and HER2-negative) tumours. This evidence concerns the gene PGR and breast cancer.